Rear Window
Ozempic seller Eucalyptus writes its own bona fides
It’s a brave new world of weight loss. But not everything has changed. Marketing a pharmaceutical program, even over the internet, remains by the book.
Myriam RobinRear Window editorAn online weight-loss start-up backed by the leading lights of Australia’s VC industry has been lauded in online media reports for “blitzing clinical trials”, after analysing the results of surveys filled out by the 6 per cent of its patients who stuck with its program and answered questions about it at week 32.
This research, of the decidedly non-clinical variety, was published by two of its employees in a prestigious and peer reviewed medical journal, whose editor-in-chief is, coincidentally, on said start-up’s advisory board.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Health & education
Fetching latest articles